Actively Recruiting
Evaluation of the Role of Connected Scales in the Therapeutic Care of Hematology Patients
Led by Assistance Publique - Hôpitaux de Paris · Updated on 2025-09-15
30
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
Sponsors
A
Assistance Publique - Hôpitaux de Paris
Lead Sponsor
W
Withings
Collaborating Sponsor
AI-Summary
What this Trial Is About
Researchers are evaluating the use of connected scales for remote monitoring in patients with aggressive non-Hodgkin's lymphoma or multiple myeloma who require chemotherapy treatment. This study aims to assess if daily weight measurements collected through a connected scale can help the medical team detect early changes in clinical parameters and improve patient care. The study is sponsored by Assistance Publique - H f4pitaux de Paris and involves 30 patients. Participants will use a connected scale called "Body Comp Pro" from Withings once daily for about 7 weeks. Their weight and other clinical data will be monitored remotely via a platform accessible to the medical team. Alerts will be generated if abnormal changes occur, allowing timely medical interventions. The study focuses on how well patients accept and use the device and how it affects their care. During the study, patients will weigh themselves daily, ideally at the same time each day. The medical team will review the data and alerts remotely. Researchers will assess patient participation rates, ease of device use, anxiety related to the device, and the impact of alerts on care throughout the 7-week period. Participation requires signing informed consent, and the total involvement duration is approximately seven weeks.
CONDITIONS
Brief Title
Evaluation of the Role of Connected Scales in the Therapeutic Care of Hematology Patients
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patient aged 18 and over (male or female)
- Diagnosed with aggressive non-Hodgkin's lymphoma or multiple myeloma and planned for systemic chemotherapy, or having started two cycles or less
- Patient needing therapeutic intensification under autograft for myeloma or lymphoma
- Able to be contacted by telephone during the study
- Able to return home after initial hospitalization
- Affiliated to social security
- Able to read and speak French
- Signed free, informed, and written consent
You will not qualify if you...
- Estimated life expectancy less than 3 months
- Moderate to severe cognitive impairment (MMSE score less than 20)
- Psychiatric or physical disability preventing use of the device
- Presence of a pacemaker
- Participation in another intervention research project
- Pregnant patient
- Patient deprived of liberty
- Under legal protection such as guardianship or curatorship
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - 7 weeks
Participants use a connected scale once a day from inclusion to Week 7. The medical team remotely monitors data and may generate alerts for early patient management.
Daily use of the connected scale
Trial Site Locations
Total: 1 location
1
Cochin Hospital
Paris, France, 75014
Actively Recruiting
Research Team
R
Rudy BIRSEN, Dr
E
Elodie LEMADRE, Mrs
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
PREVENTION
Number of Arms
1
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here